XORTX Announces Change of Effective Date of Share Consolidation
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on therapies for gout and progressive kidney disease, announced a delay in the effective date of its 1-for-5 share consolidation from March 27, 2026, to April 6, 2026. The consolidation remains subject to necessary approvals from the TSX Venture Exchange and Nasdaq Stock …